$LNTH

Lantheus Holdings, Inc. (LNTH): Submission of Matters to a Vote of Security Holders

Lantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders A special meeting of stockholders (the “special meeting”) of Lantheus Holdings, Inc. (“Lantheus”) was held on October 14, 2026. A total of 57,184,503 shares of Lantheus common stock, out of a total of 65,299,875 shares

Original reporting
Published Oct 14, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$LNTH
Bullish
high confidence
Mentioned
$LNTH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LNTHBullishLow
01

Why it matters

The approval removes a major execution risk, likely prompting a short‑term rally.

02

Market read

Merger approval is a material corporate event for LNTH, creating immediate trading relevance.

03

What to watch

Potential antitrust review and financing terms of the parent could affect ultimate value.

Relevance 6/10Novelty 8/10Timing: immediate, post‑filing today

Background

The filing reports the results of a special shareholder meeting where a merger with Curium US Holdings was approved.

Company-level read

Ticker impact

$LNTHBullishHigh confidence
Context

Lantheus shareholders approved the merger agreement and advisory compensation in an 8‑K filing, confirming the deal.

Expected impact

upward pressure as market prices in the completed merger

Evidence & confidence

The 8‑K is the first public disclosure of shareholder approval, removing deal uncertainty.

Market effects

Consolidation in the diagnostic imaging sector may prompt re‑valuation of peers.

US healthcare investors may adjust exposure to imaging companies.

Limited to US‑listed healthcare space.

Counterpoint

If regulatory or integration risks emerge, the stock could face downside despite approval.

Key entities

  • Lantheus Holdings, Inc.

    US‑listed diagnostic imaging company (ticker LNTH).

  • Curium US Holdings LLC

    Parent entity acquiring Lantheus.

Related articles

$LNTHMed

Lantheus Holdings, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger by and among the Company, Curium US Holdings LLC, a Delaware…

Lantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on August 3, 2026, Lantheus Holdings, Inc., a Delaware corporation (“ Lantheus ” or the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, Curium US Holdings LLC, a Delaw

$LNTHMed

Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)

Lantheus (NASDAQ: LNTH) announced CMS granted Transitional Pass-Through payment status for PYLARIFY® TruVu (piflufolastat F 18), effective October 1, 2026. This designation enables separate reimbursement in hospital outpatient settings, supporting access to the diagnostic radiopharmaceutical for Medicare beneficiaries. PYLARIFY TruVu is a new formulation of Lantheus’ PSMA-targeted PET imaging agent for prostate cancer, with a permanent HCPCS code assigned for billing and reimbursement.